AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27206575 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg for 7 days followed by chlorthalidone 25 mg for 14 days (coadministered from day 15).
Number of subjects: 57
Study 27206575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg for 13 days followed by coadministration with telmisartan 80 mg for 7 days.
Number of subjects: 57
Study 27206943 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (EZE) 10 mg
Number of subjects: 348
Study 27206943 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 120 mg
Number of subjects: 348
Study 27206943 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 180 mg
Number of subjects: 348
Study 27206943 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 120 mg plus EZE
Number of subjects: 348
Study 27206943 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 180 mg plus EZE
Number of subjects: 348
Study 27206943 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 alone or combined with EZE
Number of subjects: 348
Study 27207315 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld SPECT with CT-guided radioactive marking (25-30 MBq Tc-99m MAA)
Number of subjects: 10
Study 27207436 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (Compass) for assessing elbow extension range of motion (EE-ROM) during the Upper Limb Neurodynamic Test 1 (ULNT1)
Number of subjects: 41
Study 27207436 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone measurements
Number of subjects: 41
Study 27207512 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 55
Study 27207512 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with PPARG G allele
Number of subjects: 55
Study 27207512 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients noncarriers of PPARGC1A A allele
Number of subjects: 55
Study 27207512 — intervention group
Group type: COMPARATOR
Intervention: Glucose-tolerant humans (control)
Number of subjects: 55
Study 27207532 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus on chromosome 1, rs7533564
Number of subjects: 1359
Study 27207544 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 0
Study 27207544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 0
Study 27207544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both glucose and fructose ingestion
Number of subjects: 0
Study 27207788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib 70 mg/m(2) with dexamethasone (40 mg) on days 1, 8, 15, and 22; dexamethasone omitted on day 22 for cycles 9+.
Number of subjects: 116
Study 27207914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 88
Study 27207914 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 88
Study 27207972 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD
Number of subjects: 115
Study 27207972 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PAD
Number of subjects: 115
Study 27207972 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with extensive involvement of PAD or severe PAD
Number of subjects: 115
Study 27207972 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic angiography
Number of subjects: 115
Study 27208000 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Ready intervention (peer-led, workshop-based, health behavior intervention)
Number of subjects: 101
Study 27208000 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Ready intervention
Number of subjects: 101
Study 27208317 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-Hour Test
Number of subjects: 0
Study 27208317 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-Hour Test
Number of subjects: 0
Study 27208316 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight-only closed-loop control (CLC)
Number of subjects: 30
Study 27208316 — intervention group
Group type: EXPERIMENTAL
Intervention: 24/7 closed-loop control (CLC)
Number of subjects: 30
Study 27208344 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified human pancreatic islets (PHPI) with immunosuppression
Number of subjects: 48
Study 27208903 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 at 35 mg/m² b.i.d.
Number of subjects: 29
Study 27209012 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly plus methotrexate for 36 weeks
Number of subjects: 762
Study 27209254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 1000
Study 27209293 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (5-90 µg/m²/day) administered via continuous intravenous infusion for 4-8 weeks per cycle
Number of subjects: 0
Study 27209293 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 27210906 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 9068
Study 27210906 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 9068
Study 27211104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α)
Number of subjects: 0
Study 27211503 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically Controlled Capsule Endoscopy (MCE)
Number of subjects: 350
Study 27211612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human heparan-N-sulfatase (rhHNS) 10, 45, or 90mg via IDDD once monthly for a total of 6 doses
Number of subjects: 12
Study 27211612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human heparan-N-sulfatase (rhHNS)
Number of subjects: 12
Study 27212246 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2/5-PBGD administration
Number of subjects: 8
Study 27212697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) therapy after chemotherapy (CT cohort)
Number of subjects: 290
Study 27212697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) therapy as adjuvant therapy (HT cohort)
Number of subjects: 290
Study 27212955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified anticipatory guidance program in the nursery
Number of subjects: 323
Study 27212955 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 323
Study 27212955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 323
Study 27213629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) apheresis (specific immunosorbent to Lp(a)), removed weekly for 18 months.
Number of subjects: 0
Study 27213629 — intervention group
Group type: COMPARATOR
Intervention: Various lipoprotein apheresis systems (not specified), effective in removing both Lp(a) and LDL.
Number of subjects: 0
Study 27213625 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group community information sessions
Number of subjects: 127
Study 27213625 — intervention group
Group type: COMPARATOR
Intervention: One-on-one recruitment sessions
Number of subjects: 127
Study 27213625 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group sessions
Number of subjects: 127
Study 27213625 — intervention group
Group type: COMPARATOR
Intervention: One-on-one sessions
Number of subjects: 127
Study 27213850 — intervention group
Group type: EXPERIMENTAL
Intervention: hpNSCs (human parthenogenetic stem cell-derived neural stem cells)
Number of subjects: 0
Study 27214046 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) plus Methotrexate (MTX)
Number of subjects: 309
Study 27214241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 138
Study 27214597 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 9649
Study 27214597 — intervention group
Group type: COMPARATOR
Intervention: Functional diagnostic testing strategies
Number of subjects: 9649
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EGD and Colonoscopy
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral TART findings
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal endoscopic findings
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific vertebral TART findings
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Chapman reflex point tenderness
Number of subjects: 66
Study 27214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific visceral sphincter tenderness
Number of subjects: 66
Study 27215497 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication
Number of subjects: 1200
Study 27215497 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-related symptom and quality of life questionnaires
Number of subjects: 1200
Study 27215497 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection on medication use, asthma exacerbation data, asthma-related healthcare utilization and events raising safety concerns
Number of subjects: 1200
Study 27215559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy during quit attempts (used by women)
Number of subjects: 267
Study 27215559 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking and substance use (observed in men)
Number of subjects: 267
Study 27215559 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma rates (observed in women)
Number of subjects: 267
Study 27215559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation rates (male vs female smokers)
Number of subjects: 267
Study 27215559 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychobehavioral domains (male vs female smokers)
Number of subjects: 267
Study 27215749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg BID
Number of subjects: 1210
Study 27215749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1210
Study 27215927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical transcatheter aortic valve replacement (TA-TAVR)
Number of subjects: 1100
Study 27216195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T treatment
Number of subjects: 0
Study 27216195 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors
Number of subjects: 0
Study 27216309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainer phenotype (n=222)
Number of subjects: 470
Study 27216309 — intervention group
Group type: COMPARATOR
Intervention: Constrictor phenotype (n=109)
Number of subjects: 470
Study 27216309 — intervention group
Group type: COMPARATOR
Intervention: Intermediate phenotype (n=139)
Number of subjects: 470
Study 27216309 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 470
Study 27216309 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 470
Study 27216309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 470
Study 27216760 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent inactivated influenza vaccines (TIIVs)
Number of subjects: 375
Study 27216947 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 402
Study 27217067 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term high altitude exposure (3454 m)
Number of subjects: 16
Study 27217450 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-Gene Recurrence Score (RS) in B-28 patients
Number of subjects: 1733
Study 27217450 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-Gene Recurrence Score (RS) in B-14 patients
Number of subjects: 1733
Study 27217543 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly targeted therapies (MTT)
Number of subjects: 0
Study 27217543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence method
Number of subjects: 0
Study 27217543 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-TWiST method
Number of subjects: 0
Study 27217543 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival
Number of subjects: 0
Study 27218483 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 122
Study 27219495 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer ID ultra-deep sequencing approach
Number of subjects: 12
Study 27219621 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT (high-sensitive cardiac-troponin T)
Number of subjects: 227
Study 27219621 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal pro-Brain natriuretic peptide)
Number of subjects: 227
Study 27219621 — intervention group
Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 227
Study 27219621 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM (mid-regional pro-adrenomedullin)
Number of subjects: 227
Study 27219621 — intervention group
Group type: EXPERIMENTAL
Intervention: copeptin and MR-proADM
Number of subjects: 227
Study 27220948 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom distress (measured with Memorial Symptoms Assessment Scale)
Number of subjects: 104
Study 27220948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life inventory
Number of subjects: 104
Study 27220948 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys completed during the last 12 weeks of life
Number of subjects: 104
Study 27221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible severe bacterial infection (pSBI)
Number of subjects: 248539
Study 27221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Case fatality rates
Number of subjects: 248539
Study 27221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trends in incidence of pSBI
Number of subjects: 248539
Study 27221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Case fatality rates over time
Number of subjects: 248539
Study 27221125 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 (N=696, 18.8%) - emotional and physical violence by parents and relatives, and sexual and emotional abuse by boyfriends, girlfriends and unrelated adults outside school
Number of subjects: 3706
Study 27221125 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (N=975, 26.3%) - physical, emotional and sexual violence by peers (male and female students)
Number of subjects: 3706
Study 27221125 — intervention group
Group type: COMPARATOR
Intervention: Class 3 (N=2035, 54.9%) - physical violence by school staff and lower probability of all other forms of violence
Number of subjects: 3706
Study 27221128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment for grading fibrillar disruption
Number of subjects: 40
Study 27221128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment for grading neovascularity
Number of subjects: 40
Study 27221128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment for number of calcifications
Number of subjects: 40
Study 27221128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment for total length of calcifications
Number of subjects: 40
Study 27221128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment for tendon thickness
Number of subjects: 40
Study 27221128 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised procedure for ultrasound measurements
Number of subjects: 40
Study 27222461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealing with diarrhea patients
Number of subjects: 204
Study 27222461 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of liquid stools
Number of subjects: 204
Study 27222461 — intervention group
Group type: EXPERIMENTAL
Intervention: Human resources cost burden
Number of subjects: 204
Study 27222461 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall impact of diarrhea
Number of subjects: 204
Study 27222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine combination
Number of subjects: 97
Study 27222506 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Sensor
Number of subjects: 0
Study 27222654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 13
Study 27222654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27222760 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release
Number of subjects: 614
Study 27222760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 27223498 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS + BRAFi
Number of subjects: 87
Study 27223498 — intervention group
Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 87
Study 27224553 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4 levels in CHF patients
Number of subjects: 101
Study 27224553 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 101
Study 27225242 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 9
Study 27225242 — intervention group
Group type: COMPARATOR
Intervention: ledipasvir/sofosbuvir for 12 weeks
Number of subjects: 9
Study 27225680 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-family supportive organisational intervention (4-month duration)
Number of subjects: 1524
Study 27225680 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1524
Study 27225680 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-family supportive organisational intervention (4-month duration) among US-born White nursing assistants
Number of subjects: 1524
Study 27226434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg plus low-dose dexamethasone 40 mg (20 mg for patients aged >75 years)
Number of subjects: 682
Study 27226434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg plus low-dose dexamethasone
Number of subjects: 682
Study 27227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 51
Study 27227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 51
Study 27227701 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (no psychiatric history)
Number of subjects: 51
Study 27227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD) and Major Depressive Disorder (MDD)
Number of subjects: 51
Study 27227751 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening positive for depression (assessed 1-2 days postpartum)
Number of subjects: 1073
Study 27227751 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening positive for anxiety (assessed 1-2 days postpartum)
Number of subjects: 1073
Study 27227751 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum complications
Number of subjects: 1073
Study 27227751 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive history
Number of subjects: 1073
Study 27227751 — intervention group
Group type: EXPERIMENTAL
Intervention: Heightened self-efficacy
Number of subjects: 1073
Study 27228998 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon alfa-2a/ribavirin
Number of subjects: 165
Study 27229772 — intervention group
Group type: EXPERIMENTAL
Intervention: Crave-Out mobile game
Number of subjects: 30
Study 27230813 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain stimulation methods (noninvasive and invasive neuromodulatory techniques)
Number of subjects: 0
Study 27231722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 27231722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27232186 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 65000
Study 27232186 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 65000
Study 27232186 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative individuals
Number of subjects: 65000
Study 27232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label ketamine infusions (0.5 mg/kg over 45 minutes for the first 3 infusions; 0.75 mg/kg over 45 minutes for the last 3)
Number of subjects: 14
Study 27232579 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 700 mg intravenously every 2 weeks for 22 weeks
Number of subjects: 18
Study 27232917 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension (51.6% of patients)
Number of subjects: 5220
Study 27232917 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent resistant hypertension (14.3% of patients)
Number of subjects: 5220
Study 27232917 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with uncontrolled hypertension
Number of subjects: 5220
Study 27232917 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with apparent resistant hypertension
Number of subjects: 5220
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (ABT-199/GDC-0199)
Number of subjects: 505
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CYP3A inhibitors
Number of subjects: 505
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong CYP3A inhibitors
Number of subjects: 505
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 505
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Food
Number of subjects: 505
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild and moderate renal and hepatic impairment, body weight, age, race, weak CYP3A inhibitors and inducers, OATP1B1 transporter phenotype, P-gp, BCRP, and OATP1B1/OATP1B3 modulators
Number of subjects: 505
Study 27233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 505
Study 27234335 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension at diagnosis of diabetes
Number of subjects: 327
Study 27234335 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 327